MAPT and cerebral amyloid angiopathy: To further characterize the GWS variants with respect to other AD-related phenotypes, we evaluated their association with AD risk, AD-related neuropathological variables (Braak stage, Thal phase, cerebral amyloid angiopathy = CAA), AD-related biomarkers (amyloid [18F] Florbetapir PET scans, plasma total Aβ42, and phosphorylated tau (pTau), CSF Aβ42, total tau (t-tau) and pTau) and age at death in additional samples.